Compare Johnson Controls International PLC (JCI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs Sana Biotechnology Inc — how do they compare? Johnson Controls International PLC trades at $157.44 (market cap $93.28B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Johnson Controls International PLC is far larger — about 111.5× Sana Biotechnology Inc's market cap, and Johnson Controls International PLC pays a 1.04% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson Controls International PLC for 65 Days and Sana Biotechnology Inc for 23 Days on average.
| JCI | SANA | |
|---|---|---|
Market Cap | $93.28B | $836.71M |
Volume | 2,786,476 | 4,507,444 |
Sector | Basic Materials | Health |
52-Week High | $158.76 | $5.92 |
52-Week Low | $105.55 | $2.68 |
Typical Hold Time | 65 Days | 23 Days |
Enterprise Value | $102.12B | $749.96M |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson Controls International (JCI) trades at $157.44, up 0.97% on the day, reflecting strong momentum after beating earnings estimates for three consecutive quarters. The stock exhibits a bullish technical outlook, trading above key support levels, while fundamentals are supported by a 13.94% net income margin and robust ROE of 24.42%. Recent news highlights inclusion in AI industrial stock recommendations and strong Q3 2026 results with raised full-year guidance.
The outlook for JCI remains positive, driven by earnings outperformance and strong demand in thermal management and building systems. Key opportunities include expanding margins and strategic positioning in energy efficiency markets. Risks involve elevated valuation multiples and increasing debt-to-asset ratios, which could pressure the stock if growth moderates.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
